FI3708579T3 - Claudin-6-spesifiset immuunoreseptorit ja t-soluepitoopit - Google Patents
Claudin-6-spesifiset immuunoreseptorit ja t-soluepitoopit Download PDFInfo
- Publication number
- FI3708579T3 FI3708579T3 FIEP20160141.6T FI20160141T FI3708579T3 FI 3708579 T3 FI3708579 T3 FI 3708579T3 FI 20160141 T FI20160141 T FI 20160141T FI 3708579 T3 FI3708579 T3 FI 3708579T3
- Authority
- FI
- Finland
- Prior art keywords
- cancer
- nucleic acid
- seo
- amino acid
- acid sequence
- Prior art date
Links
- 102000027596 immune receptors Human genes 0.000 title 1
- 108091008915 immune receptors Proteins 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 claims 20
- 150000007523 nucleic acids Chemical class 0.000 claims 20
- 102000039446 nucleic acids Human genes 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 102000003859 Claudin-6 Human genes 0.000 claims 8
- 108090000229 Claudin-6 Proteins 0.000 claims 8
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010061252 Intraocular melanoma Diseases 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 201000005746 Pituitary adenoma Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 230000005754 cellular signaling Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000002575 ocular melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000003913 parathyroid carcinoma Diseases 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims 1
- 201000011453 reproductive organ cancer Diseases 0.000 claims 1
- 208000015608 reproductive system cancer Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2014000868 | 2014-04-01 | ||
| EP2014072864 | 2014-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3708579T3 true FI3708579T3 (fi) | 2024-07-16 |
Family
ID=52745896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20160141.6T FI3708579T3 (fi) | 2014-04-01 | 2015-03-30 | Claudin-6-spesifiset immuunoreseptorit ja t-soluepitoopit |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10370423B2 (enExample) |
| EP (3) | EP3514172B1 (enExample) |
| JP (3) | JP6726656B2 (enExample) |
| CN (3) | CN106459165B (enExample) |
| AU (3) | AU2015239683B2 (enExample) |
| CA (1) | CA2942459C (enExample) |
| CY (1) | CY1121539T1 (enExample) |
| DK (3) | DK3708579T3 (enExample) |
| ES (3) | ES2982838T3 (enExample) |
| FI (1) | FI3708579T3 (enExample) |
| HR (2) | HRP20240926T1 (enExample) |
| HU (3) | HUE067504T2 (enExample) |
| LT (2) | LT3126381T (enExample) |
| ME (1) | ME03407B (enExample) |
| MX (1) | MX376026B (enExample) |
| PL (3) | PL3708579T3 (enExample) |
| PT (3) | PT3708579T (enExample) |
| RS (2) | RS58627B2 (enExample) |
| SI (3) | SI3708579T1 (enExample) |
| SM (1) | SMT201900262T1 (enExample) |
| WO (1) | WO2015150327A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20171749T1 (hr) | 2009-11-11 | 2018-01-26 | Ganymed Pharmaceuticals Gmbh | Protutijela specifična za claudin 6 (cldn6) |
| ES2702315T3 (es) | 2012-08-24 | 2019-02-28 | Univ California | Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis |
| RU2016122041A (ru) | 2013-11-06 | 2017-12-11 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Новые анти-клаудин антитела и способы их применения |
| MA40921A (fr) * | 2014-11-05 | 2017-09-12 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation |
| EP3808770B1 (en) | 2014-11-14 | 2025-10-29 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Anti-thyroglobulin t cell receptors |
| CN106146666B (zh) * | 2015-03-26 | 2019-09-06 | 科济生物医药（上海）有限公司 | 靶向cldn6的免疫效应细胞及其制备方法和应用 |
| WO2016180467A1 (en) | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination |
| WO2016180468A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Claudin-18.2-specific immunoreceptors and t cell epitopes |
| EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| KR20190080992A (ko) | 2015-05-21 | 2019-07-08 | 하푼 테라퓨틱스, 인크. | 삼중특이성 결합 단백질 및 사용 방법 |
| GB201607534D0 (en) | 2016-04-29 | 2016-06-15 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| MA55153A (fr) | 2016-02-19 | 2021-09-29 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers |
| KR102497013B1 (ko) | 2016-06-07 | 2023-02-20 | 맥스-델브뤼크-센트럼 퓌어 몰레쿨라레 메디친 | Bcma에 결합하는 키메라 항원 수용체 및 car-t 세포 |
| MX2018016330A (es) | 2016-06-27 | 2020-02-17 | Univ California | Combinaciones para tratamiento del cáncer. |
| BR112019000512A2 (pt) | 2016-07-14 | 2019-04-24 | Genmab A/S | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit |
| BR112019007100A2 (pt) * | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão |
| AU2017366739B2 (en) | 2016-12-02 | 2023-11-23 | Angeles Therapeutics, Inc. | Synthetic immune receptors and methods of use thereof |
| MX2019010972A (es) * | 2017-03-15 | 2019-12-02 | Hutchinson Fred Cancer Res | Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos. |
| US20210122831A1 (en) * | 2017-03-27 | 2021-04-29 | Noile-Immune Biotech, Inc. | Chimeric antigen receptor |
| KR102758346B1 (ko) | 2017-08-04 | 2025-01-24 | 젠맵 에이/에스 | Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도 |
| CN118667021A (zh) * | 2017-09-18 | 2024-09-20 | 加利福尼亚大学董事会 | 紧密连接蛋白6抗体和治疗癌症的方法 |
| AU2018342527B2 (en) | 2017-09-29 | 2024-06-27 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN120983617A (zh) | 2018-11-06 | 2025-11-21 | 健玛保 | 抗体配制剂 |
| MX2021005308A (es) * | 2018-11-09 | 2021-09-08 | Fred Hutchinson Cancer Center Star | Receptores de celulas t especificos para mesotelina y su uso en inmunoterapia. |
| JP7671248B2 (ja) * | 2018-12-05 | 2025-05-01 | ジェネンテック， インコーポレイテッド | がんの免疫療法のための診断方法及び診断用組成物 |
| US20220184119A1 (en) * | 2019-02-08 | 2022-06-16 | Biontech Cell & Gene Therapies Gmbh | Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancers |
| CN114174829A (zh) * | 2019-03-01 | 2022-03-11 | 磨石生物公司 | T细胞受体的选择 |
| BR112021018608A2 (pt) | 2019-03-20 | 2021-11-23 | Univ California | Anticorpos para claudina-6 e conjugados de fármaco |
| WO2021129927A1 (en) * | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
| EP4100059A1 (en) | 2020-02-04 | 2022-12-14 | Genmab A/S | Antibodies for use in therapy |
| AU2021380005A1 (en) | 2020-11-11 | 2023-06-01 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
| WO2022147075A1 (en) * | 2020-12-30 | 2022-07-07 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors targeting splice variants of the extracellular matrix proteins tenascin c (tnc) and procollagen 11a1 (col11a1) |
| US20240262924A1 (en) | 2021-06-21 | 2024-08-08 | Genmab A/S | Combination dosage regime of cd137 and pd-l1 binding agents |
| AU2022312698A1 (en) | 2021-07-13 | 2024-01-25 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| KR20240073008A (ko) * | 2021-09-03 | 2024-05-24 | 노바록 바이오테라퓨틱스 리미티드 | Cd137 및 종양 연관 항원에 결합하는 이중특이적 결합 단백질 |
| JP2024536383A (ja) | 2021-10-06 | 2024-10-04 | ジェンマブ エー／エス | 併用におけるｐｄ－ｌ１およびｃｄ１３７に対する多重特異性結合剤 |
| JP2024538755A (ja) | 2021-10-06 | 2024-10-23 | ジェンマブ エー／エス | がんを処置するための、抗ｐｄ－１抗体との組合せにおけるｐｄ－ｌ１及びｃｄ１３７に対する多特異性結合剤 |
| CA3234897A1 (en) * | 2021-10-14 | 2023-04-20 | Kunle Odunsi | Compositions and methods for use of recombinant t cell receptors against claudin 6 |
| IL316628A (en) | 2022-05-12 | 2024-12-01 | Genmab As | Binding agents capable of binding to CD27 in combination therapy |
| US20250325643A1 (en) | 2022-05-12 | 2025-10-23 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
| EP4522654A1 (en) | 2022-05-12 | 2025-03-19 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
| CN115232207B (zh) * | 2022-05-19 | 2023-06-13 | 河南大学 | 抗体-溶菌素（SM-ScFv-Fc-Ly）在治疗变形链球菌感染中的应用 |
| WO2024165057A1 (en) * | 2023-02-07 | 2024-08-15 | LaNova Medicines Limited | Antibodies and antibody-drug conjugates targeting claudin 6 |
| WO2024209072A1 (en) | 2023-04-06 | 2024-10-10 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 for treating cancer |
| WO2024243561A1 (en) | 2023-05-25 | 2024-11-28 | The Regents Of The University Of California | Methods of treating cancer |
| WO2025114541A1 (en) | 2023-11-30 | 2025-06-05 | Genmab A/S | Antibodies capable of binding to ox40 in combination therapy |
| WO2025184170A1 (en) | 2024-02-27 | 2025-09-04 | Overt Bio, Inc. | Methods and compositions for improving t cell function in an immunosuppressive environment |
| CN118812714B (zh) * | 2024-08-21 | 2025-05-27 | 广州百吉生物制药有限公司 | 一种紧密连接蛋白抗体b3及其应用 |
| CN119320451B (zh) * | 2024-08-21 | 2025-05-16 | 百吉生物医药(广州)股份有限公司 | 一种紧密连接蛋白抗体d03及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677139A (en) | 1995-04-21 | 1997-10-14 | President And Fellows Of Harvard College | In vitro differentiation of CD34+ progenitor cells into T lymphocytes |
| EP0871747A1 (en) | 1996-01-02 | 1998-10-21 | Chiron Viagene, Inc. | Immunostimulation mediated by gene-modified dendritic cells |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7435596B2 (en) * | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| AU2006293420B2 (en) * | 2005-09-22 | 2011-06-30 | Irun R. Cohen | Immunogenic fragments of T-cell receptor constant domains and peptides derived therefrom |
| AU2007332473B2 (en) | 2006-12-14 | 2012-09-27 | Forerunner Pharma Research Co., Ltd. | Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same |
| EP2138576A4 (en) | 2007-03-16 | 2011-02-23 | Kyowa Hakko Kirin Co Ltd | ANTI-CLAUDIN-4 ANTIBODY |
| AU2009203464A1 (en) * | 2008-01-11 | 2009-07-16 | Forerunner Pharma Research Co., Ltd. | Anti-CLDN6 antibody |
| NZ594480A (en) * | 2009-02-20 | 2013-11-29 | Ganymed Pharmaceuticals Ag | Methods and compositions for diagnosis and treatment of cancer |
| HRP20171749T1 (hr) * | 2009-11-11 | 2018-01-26 | Ganymed Pharmaceuticals Gmbh | Protutijela specifična za claudin 6 (cldn6) |
| EP2322555A1 (en) * | 2009-11-11 | 2011-05-18 | Ganymed Pharmaceuticals AG | Antibodies specific for claudin 6 (CLDN6) |
| TR201809413T4 (tr) * | 2010-03-16 | 2018-07-23 | Biontech Protein Therapeutics Gmbh | Self-protein cldn18.2 ye karşı bir humoral immün yanıtı içeren tümor aşılama. |
| CA2795643C (en) * | 2010-04-13 | 2018-07-17 | Sigma-Aldrich Co. Llc | Methods for generating endogenously tagged protein |
| EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| ES2656414T3 (es) * | 2010-09-08 | 2018-02-27 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| AU2012258087B2 (en) * | 2011-05-13 | 2017-07-20 | Astellas Pharma Inc. | Antibodies for treatment of cancer expressing claudin 6 |
| KR20140127816A (ko) | 2012-02-22 | 2014-11-04 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암의 치료에 유용한 t 세포의 지속성 집단을 생성시키기 위한 조성물 및 방법 |
-
2015
- 2015-03-30 DK DK20160141.6T patent/DK3708579T3/da active
- 2015-03-30 AU AU2015239683A patent/AU2015239683B2/en active Active
- 2015-03-30 DK DK19151238.3T patent/DK3514172T3/da active
- 2015-03-30 DK DK15712657.4T patent/DK3126381T4/da active
- 2015-03-30 CN CN201580017607.3A patent/CN106459165B/zh active Active
- 2015-03-30 US US15/124,640 patent/US10370423B2/en active Active - Reinstated
- 2015-03-30 LT LTEP15712657.4T patent/LT3126381T/lt unknown
- 2015-03-30 RS RS20190361A patent/RS58627B2/sr unknown
- 2015-03-30 JP JP2017503063A patent/JP6726656B2/ja active Active
- 2015-03-30 PL PL20160141.6T patent/PL3708579T3/pl unknown
- 2015-03-30 FI FIEP20160141.6T patent/FI3708579T3/fi active
- 2015-03-30 ES ES20160141T patent/ES2982838T3/es active Active
- 2015-03-30 HR HRP20240926TT patent/HRP20240926T1/hr unknown
- 2015-03-30 PL PL19151238T patent/PL3514172T3/pl unknown
- 2015-03-30 PL PL15712657T patent/PL3126381T5/pl unknown
- 2015-03-30 SM SM20190262T patent/SMT201900262T1/it unknown
- 2015-03-30 LT LTEP20160141.6T patent/LT3708579T/lt unknown
- 2015-03-30 HU HUE20160141A patent/HUE067504T2/hu unknown
- 2015-03-30 CA CA2942459A patent/CA2942459C/en active Active
- 2015-03-30 PT PT201601416T patent/PT3708579T/pt unknown
- 2015-03-30 HR HRP20190472TT patent/HRP20190472T4/hr unknown
- 2015-03-30 MX MX2016012713A patent/MX376026B/es active IP Right Grant
- 2015-03-30 SI SI201532019T patent/SI3708579T1/sl unknown
- 2015-03-30 EP EP19151238.3A patent/EP3514172B1/en active Active
- 2015-03-30 ES ES19151238T patent/ES2784537T3/es active Active
- 2015-03-30 EP EP15712657.4A patent/EP3126381B2/en active Active
- 2015-03-30 HU HUE19151238A patent/HUE050355T2/hu unknown
- 2015-03-30 PT PT15712657T patent/PT3126381T/pt unknown
- 2015-03-30 PT PT191512383T patent/PT3514172T/pt unknown
- 2015-03-30 ES ES15712657T patent/ES2717530T5/es active Active
- 2015-03-30 SI SI201531143T patent/SI3514172T1/sl unknown
- 2015-03-30 WO PCT/EP2015/056899 patent/WO2015150327A1/en not_active Ceased
- 2015-03-30 CN CN202110278993.9A patent/CN113150109A/zh active Pending
- 2015-03-30 ME MEP-2019-67A patent/ME03407B/me unknown
- 2015-03-30 EP EP20160141.6A patent/EP3708579B1/en active Active
- 2015-03-30 RS RS20240864A patent/RS65784B1/sr unknown
- 2015-03-30 SI SI201530629T patent/SI3126381T2/sl unknown
- 2015-03-30 HU HUE15712657 patent/HUE044515T2/hu unknown
- 2015-03-30 CN CN202110279207.7A patent/CN113150110A/zh active Pending
-
2019
- 2019-04-02 CY CY20191100366T patent/CY1121539T1/el unknown
- 2019-06-18 US US16/444,510 patent/US11345731B2/en active Active
- 2019-07-31 AU AU2019210582A patent/AU2019210582B2/en active Active
-
2020
- 2020-02-19 JP JP2020025935A patent/JP6985440B2/ja active Active
-
2021
- 2021-05-31 AU AU2021203528A patent/AU2021203528B2/en active Active
- 2021-11-25 JP JP2021190855A patent/JP7451858B2/ja active Active
-
2022
- 2022-04-04 US US17/712,562 patent/US20220306711A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3708579T3 (fi) | Claudin-6-spesifiset immuunoreseptorit ja t-soluepitoopit | |
| RU2018111462A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток | |
| RU2019133199A (ru) | Улучшенные форматы антигенсвязывающего рецептора | |
| RU2018134771A (ru) | Клетки, экспрессирующие множество молекул химерных антигенных рецепторов (car), и их применение | |
| JP2019513347A5 (enExample) | ||
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| RU2017121892A (ru) | Клетка | |
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| FI3240805T3 (fi) | Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori | |
| JP2016534717A5 (enExample) | ||
| HRP20220131T1 (hr) | Nova terapija s t-staničnim receptorima i imunološka terapija koja koristi iste | |
| RU2018113510A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
| HRP20220799T1 (hr) | Klaudin-18-2-specifični imunoreceptori i stanični epitopi t | |
| IL264144B2 (en) | Antibody 18A2 against CLAUDIN and its use | |
| RU2016138422A (ru) | Химерный антигенный рецептор | |
| RU2019105693A (ru) | Лечение рака с применением химерного антигенного рецептора в комбинации с ингибитором молекулы, способствующей фенотипу m2 макрофага | |
| JP2014534207A5 (enExample) | ||
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| JP2020530989A5 (enExample) | ||
| RU2015117237A (ru) | Химерные антигенные рецепторы м971 | |
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| RU2016124280A (ru) | Клетка | |
| RU2019126655A (ru) | Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль | |
| FI2997141T3 (fi) | CD19-spesifinen kimeerinen antigeenireseptori ja sen käyttöjä | |
| JP2016508725A5 (enExample) |